Results from 96 Weeks Open-Label Extension of a Phase 2 Trial of Losmapimod in Subjects with FSHD: ReDUX4 (S48.008)Leo Wang,Jay Han,Jennifer Shoskes,John Jiang,Alrabi TawilNeurology(2023)引用 0|浏览7关键词Drug DeliveryAI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要